End of Treatment Abstinence Rates
Primary
· Week 8 (end of treatment)
7-day point prevalence abstinence
| Group | Value | 95% CI |
|---|---|---|
| Treatment Arm | 3 | |
| Standard Care | 0 |
Last reviewed · How we verify
NCT03927989
Tobacco Treatment in the Context of Lung Cancer Screening
Completed
NA
Results posted
Last updated 22 November 2024
What this trial tests
NA trial testing Text messaging plus nicotine replacement therapy in Smoking Cessation in 48 participants. Completed in 1 February 2024.
Timeline
15 April 2019
Primary endpoint
19 October 2023
19 October 2023
1 February 2024
Quick facts
| Lead sponsor | Medical University of South Carolina |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 15 April 2019 |
| Primary completion | 19 October 2023 |
| Estimated completion | 1 February 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Text messaging plus nicotine replacement therapy
- Standard Care at Lung Cancer Screening
Conditions studied
- Smoking Cessation — all drugs for Smoking Cessation →
Sponsor
Medical University of South Carolina
Who can join
55 and older, any sex, with Smoking Cessation. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
End of Study Abstinence Rates
Secondary
· 3-month follow-up
Effect size estimates at End of Study
| Group | Value | 95% CI |
|---|---|---|
| Treatment Arm | 1 | |
| Standard Care | 0 |
Sponsor's own description
The proposed study will test a medication plus text messaging intervention specifically designed for lung cancer screening patients. Half of the patients will receive standard of care, and half will receive the treatment intervention.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Predictors of Enrollment of Older Smokers in Six Smoking Cessation Trials in the Lung Cancer Screening Setting: The Smoking Cessation at Lung Examination (SCALE) Collaboration.
Eyestone E, Williams RM, Luta G, Kim E, et al · · 2021 · cited 5× · PMID 34077535 · DOI 10.1093/ntr/ntab110
Verify or expand the search:
- PubMed search for NCT03927989
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Smoking Cessation
Currently open trials in the same condition.
- NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
- NCT07224087 — Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients · Phase 1 · recruiting
- NCT07331519 — Integrating Smoking Cessation With Low-dose CT-screening for Lung Cancer · NA · recruiting
- NCT07210567 — Mindfulness-based Ecological Momentary Intervention for Smoking Cessation Among Cancer Survivors · NA · recruiting
- NCT07129590 — Trauma-Informed Care for Smoking Cessation for Pregnancy · NA · recruiting
Other Medical University of South Carolina trials
Trials by the same sponsor.
- NCT06491264 — Multiparameter Optimized tES for Memory in Aging · NA · withdrawn
- NCT07513389 — Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) · Phase 2 · not yet recruiting
- NCT03101917 — Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE) · NA · not yet recruiting
- NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors · Phase 2 · recruiting
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03927989 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of South Carolina
- Last refreshed: 22 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03927989.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing